Diabetes Drugs' Weight Loss Hype Sparks Safety Fears

As India grapples with a high diabetes prevalence, injectable GLP-1 receptor agonists have emerged as a significant advancement for managing blood sugar and weight.

However, with World Obesity Day on March 4, medical professionals are urging stricter oversight. The drugs' effectiveness in promoting rapid weight loss has led to an unprecedented demand, fueling a market for generic alternatives. Concerns are mounting over unsupervised usage and a trend of using these medications for cosmetic purposes.

To address potential abuse, a subject expert committee of the CDSCO mandated in January that these injectables must only be prescribed by registered endocrinologists. Experts emphasize that severe side effects often occur when medications are taken without medical supervision.

Physicians warn that self-adjusting doses or using these potent prescription drugs for aesthetic reasons can lead to serious health issues like electrolyte imbalances and pancreatitis. They stress that GLP-1 therapies are part of a comprehensive clinical plan, not lifestyle supplements.

Despite the risks associated with misuse, the popularity of GLP-1 drugs is seen as a positive shift, acknowledging obesity as a medical condition rather than a failure of willpower. For appropriate patients, these therapies can improve cardiovascular health and manage related conditions, but a clear distinction between medical necessity and cosmetic trends is crucial.